Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Texto completo Resumo
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
Artigos de referência
1. Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999 Apr 29;340(17):1330-40. Resumo
2. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun;23(6):1054-61. Resumo
3. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.Texto completo Resumo
4. Goldman J. ABC of clinical haematology: chronic myeloid leukaemia. BMJ. 1997 Mar 1;314(7081):657-60. [Erratum in: BMJ 1997 Mar 15;314(7083):812.]Texto completo Resumo
5. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17-48.Texto completo Resumo
6. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: leukemia - chronic myeloid leukemia (CML). 2023 [internet publication].Texto completo
7. Cancer Research UK. Chronic myeloid leukaemia (CML) incidence statistics [internet publication].Texto completo
8. Tsushima H, Iwanaga M, Miyazaki Y. Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes. Int J Hematol. 2012 Mar;95(3):232-8. Resumo
9. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15;341(3):164-72. Resumo
10. American Cancer Society. Risk factors for chronic myeloid leukemia. Jun 2018 [internet publication].Texto completo
11. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009 Jan;11(1):4-11.Texto completo Resumo
12. Adnan-Awad S, Kim D, Hohtari H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2021 Jul;35(7):1964-75.Texto completo Resumo
13. Adnan-Awad S, Hohtari H, Javarappa KK, et al. BCR-ABL1 p190 in CML: a minor breakpoint with a major impact. Blood. 2019 Nov;134(1 suppl):190.Texto completo
14. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009 Jan;89(1):14-23. Resumo
15. Kuan JW, Melaine Michael S. The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Med J Malaysia. 2018 Apr;73(2):78-85.Texto completo Resumo
16. Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012 Apr;17 Suppl 1:S72-4.Texto completo Resumo
17. Mendizabal AM, Garcia-Gonzalez P, Levine PH. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries. Cancer Epidemiol. 2013 Jun;37(3):247-54. Resumo
18. Ural AU, Beyzadeoglu M, Avcu F, et al. Chronic myeloid leukemia following radiotherapy for carcinoma of the cervix: report of a case and brief review of the literature. Am J Hematol. 2007 May;82(5):415-6.Texto completo Resumo
19. Miyoshi I, Mori M, Yamasaki I, et al. Is there an entity of radiation-induced chronic myeloid leukemia? Report of a case and brief review of the literature. J Clin Exp Hematop. 2020;60(1):24-5.Texto completo Resumo
20. Leuraud K, Richardson DB, Cardis E, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015 Jul;2(7):e276-81.Texto completo Resumo
21. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 Mar;93(3):442-59.Texto completo Resumo
22. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br J Haematol. 1997 Jan;96(1):111-6. Resumo
23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia [internet publication].Texto completo
24. Liu Z, Shi Y, Yan Z, et al. Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era. Hematology. 2020 Dec;25(1):181-5.Texto completo Resumo
25. Sevastos N, Theodossiades G, Efstathiou S, et al. Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med. 2006 Mar;147(3):139-44. Resumo
26. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(Suppl 4):iv41-51.Texto completo Resumo
27. Cross NC, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts of chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993 Sep 15;82(6):1929-36.Texto completo Resumo
28. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.Texto completo Resumo
29. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemias. Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol. 1994 Aug;87(4):746-54. Resumo
30. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007 Aug 15;110(4):1092-7.Texto completo Resumo
31. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood. 1993 Aug 1;82(3):691-703.Texto completo Resumo
32. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84.Texto completo Resumo
33. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003 May 15;101(10):3794-800.Texto completo Resumo
34. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15;117(6):1113-22.Texto completo Resumo
35. Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021 May;35(5):1344-55.Texto completo Resumo
36. Smith G, Apperley J, Milojkovic D, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020 Oct;191(2):171-93.Texto completo Resumo
37. Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Paper presented at: 51st ASH Annual Meeting. Dec 5-8, 2009. New Orleans, LA. Chronic myeloid leukemia - therapy poster. Abstract 1126. Blood. 2009 Nov 20;114(22):1126.Texto completo
38. O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13;348(11):994-1004.Texto completo Resumo
39. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009 Dec 24;114(27):5426-35.Texto completo Resumo
40. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51.Texto completo Resumo
41. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12.Texto completo Resumo
42. Talpaz M, Shah N, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41.Texto completo Resumo
43. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib. Blood. 2011 Oct 27;118(17):4567-76.Texto completo Resumo
44. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9.Texto completo Resumo
45. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. Resumo
46. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly fiagnosed vhronic myeloid leukemia: results From the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231-7.Texto completo Resumo
47. Saussele S, Haverkamp W, Lang F, et al. Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematol. 2020;143(3):217-31.Texto completo Resumo
48. Müller MC, Cervantes F, Hjorth-Hansen H, et al. Ponatinib in chronic myeloid leukemia (CML): consensus on patient treatment and management from a European expert panel. Crit Rev Oncol Hematol. 2017 Dec;120:52-9.Texto completo Resumo
49. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 7;369(19):1783-96.Texto completo Resumo
50. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].Texto completo
51. Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019 Dec 12;381(24):2315-26.Texto completo Resumo
52. Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-41.Texto completo Resumo
53. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation [internet publication].Texto completo
54. Lübking A, Dreimane A, Sandin F, et al. Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry. Bone Marrow Transplant. 2019 Nov;54(11):1764-74. Resumo
55. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996 May;17 Suppl 3:S5-6. Resumo
56. Clift RA, Anasetti C. Allografting for chronic myeloid leukemia. Baillieres Clin Haematol. 1997 Jun;10(2):319-36. Resumo
57. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007 Feb 15;109(4):1782-9.Texto completo Resumo
58. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9.Texto completo Resumo
59. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated phase chronic myelogenous leukemia - comparison with historic experience. Cancer. 2005 May 15;103(10):2099-108. Resumo
60. Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022 Feb;9(2):e121-32.Texto completo Resumo
61. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010 Jan 20;28(3):424-30.Texto completo Resumo
62. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009 May 7;113(19):4497-504.Texto completo Resumo
63. Preudhomme C, Guilhot J, Nicolini FE, et al; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21.Texto completo Resumo
64. ClinicalTrials.gov. TKI and interferon alpha evaluation initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER). NCT01657604. Aug 2021 [internet publication].Texto completo
65. Saifullah HH, Lucas CM. Treatment-free remission in chronic myeloid leukemia: can we identify prognostic factors? Cancers (Basel). 2021 Aug 19;13(16):4175.Texto completo Resumo
66. Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020 Aug;17(8):493-503. Resumo
67. Cortes J, Lipton JH, Rea D, et al; Omacetaxine 202 Study Group. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012 Sep 27;120(13):2573-80.Texto completo Resumo
68. ClinicalTrials.gov. A pivotal study of HQP1351 in patients of chronic myeloid leukemia in accelerated phase with T315I mutation. NCT03883100. May 2021 [internet publication].Texto completo
69. ClinicalTrials.gov. A pivotal study of HQP1351 in patients of chronic myeloid leukemia in chronic phase with T315I mutation. NCT03883087. May 2021 [internet publication].Texto completo
70. ClinicalTrials.gov. A pivotal study of HQP1351 in patients with chronic myeloid leukemia in chronic phase. NCT04126681. Jun 2021 [internet publication].Texto completo
71. Kantarjian H, Sawyers C, Hochhaus A, et al; International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002 Feb 28;346(9):645-52. [Erratum in: N Engl J Med. 2002 Jun 13;346(24):1923.]Texto completo Resumo
72. Hughes TP, Hochhaus A, Branford S, et al; IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010 Nov 11;116(19):3758-65.Texto completo Resumo
73. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143-50.Texto completo Resumo
74. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017 Nov 15;123(22):4391-402.Texto completo Resumo
75. Fachi MM, Tonin FS, Leonart LP, et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta-analysis. Br J Clin Pharmacol. 2019 Oct;85(10):2280-91.Texto completo Resumo
76. Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010 Jul;16(4):351-6. Resumo
77. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015 Dec 10;33(35):4210-8. Resumo
78. Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019 Mar 26;3(6):851-61.Texto completo Resumo
79. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc. 2009 Feb;84(2):161-9.Texto completo Resumo
80. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009 Nov;23(11):1957-63. Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal